Citadel Advisors
NTLA icon

Citadel Advisors’s Intellia Therapeutics NTLA Stock Holding History

Citadel Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.19M Sell
248,800
-184,300
-43% -$2.35M ﹤0.01% 5145
2025
Q4 		$3.89M Buy
433,100
+249,600
+136% +$3.44M ﹤0.01% 4708
2025
Q3 		$3.17M Sell
183,500
-3,300
-2% -$40.6K ﹤0.01% 5208
2025
Q2 		$1.75M Buy
186,800
+84,700
+83% +$696K ﹤0.01% 5956
2025
Q1 		$726K Sell
102,100
-15,400
-13% -$156K ﹤0.01% 7666
2024
Q4 		$1.37M Buy
117,500
+58,300
+98% +$910K ﹤0.01% 6402
2024
Q3 		$1.22M Sell
59,200
-67,600
-53% -$1.56M ﹤0.01% 6462
2024
Q2 		$2.84M Buy
126,800
+55,800
+79% +$1.33M ﹤0.01% 4672
2024
Q1 		$1.95M Sell
71,000
-3,500
-5% -$97.2K ﹤0.01% 5568
2023
Q4 		$2.27M Sell
74,500
-28,600
-28% -$822K ﹤0.01% 5137
2023
Q3 		$3.26M Buy
103,100
+65,900
+177% +$2.56M ﹤0.01% 4339
2023
Q2 		$1.52M Sell
37,200
-100
-0.3% -$4.05K ﹤0.01% 5660
2023
Q1 		$1.39M Sell
37,300
-39,700
-52% -$1.56M ﹤0.01% 6062
2022
Q4 		$2.69M Sell
77,000
-15,400
-17% -$732K ﹤0.01% 4936
2022
Q3 		$5.17M Sell
92,400
-39,900
-30% -$2.48M ﹤0.01% 3805
2022
Q2 		$6.85M Buy
132,300
+72,000
+119% +$3.66M ﹤0.01% 3234
2022
Q1 		$4.38M Sell
60,300
-100
-0.2% -$8.47K ﹤0.01% 4437
2021
Q4 		$7.14M Sell
60,400
-40,800
-40% -$5.11M ﹤0.01% 3675
2021
Q3 		$13.6M Sell
101,200
-107,800
-52% -$16.3M ﹤0.01% 2583
2021
Q2 		$33.8M Buy
209,000
+107,200
+105% +$8.35M 0.01% 1492
2021
Q1 		$8.17M Buy
101,800
+41,600
+69% +$2.79M ﹤0.01% 3292
2020
Q4 		$3.27M Buy
60,200
+30,100
+100% +$1.09M ﹤0.01% 4439
2020
Q3 		$598K Sell
30,100
-15,200
-34% -$317K ﹤0.01% 6961
2020
Q2 		$952K Buy
45,300
+19,200
+74% +$326K ﹤0.01% 5922
2020
Q1 		$319K Sell
26,100
-28,300
-52% -$381K ﹤0.01% 7228
2019
Q4 		$798K Sell
54,400
-36,700
-40% -$511K ﹤0.01% 5995
2019
Q3 		$1.22M Buy
91,100
+64,300
+240% +$1.03M ﹤0.01% 5252
2019
Q2 		$439K Sell
26,800
-3,100
-10% -$48.7K ﹤0.01% 7016
2019
Q1 		$511K Buy
29,900
+8,400
+39% +$125K ﹤0.01% 6755
2018
Q4 		$293K Buy
21,500
+4,300
+25% +$79.9K ﹤0.01% 7312
2018
Q3 		$492K Sell
17,200
-32,900
-66% -$957K ﹤0.01% 6732
2018
Q2 		$1.37M Buy
50,100
+26,200
+110% +$635K ﹤0.01% 4689
2018
Q1 		$504K Sell
23,900
-4,500
-16% -$111K ﹤0.01% 5875
2017
Q4 		$546K Buy
28,400
+13,400
+89% +$309K ﹤0.01% 5517
2017
Q3 		$373K Buy
+15,000
New +$283K ﹤0.01% 5725

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's NTLA Position: Q1 2026 in Review

Citadel Advisors reduced its Intellia Therapeutics (NTLA) stake by 52% in Q1 2026, selling an estimated $6.27M and leaving 458,241 shares worth $5.87M. The position accounts for ﹤0.01% of the portfolio, ranked #4079.

Citadel Advisors first reported a position in NTLA in Q3 2017 and has held it in 34 quarters since. The position peaked at $65.4M in Q2 2023. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Citadel Advisors held 458,241 shares of Intellia Therapeutics worth $5.87M as of Q1 2026.
  • Citadel Advisors sold 492,009 Intellia Therapeutics shares in Q1 2026, an estimated $6.27M.
  • Intellia Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4079 holding.
  • Citadel Advisors first reported a position in Intellia Therapeutics in Q3 2017 and has held it in 34 quarters since.
  • Citadel Advisors's Intellia Therapeutics position peaked at $65.4M in Q2 2023.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.